Our study also
set the ground to study the relevance of the metabolic milieu in affecting drug response and toxicity in diabetic versus non-diabetic patients with MM Acknowledgements JL was awarded the ASH Minority Research Award 2008-2009 that has funded part of the project while he was a medical student at LSUHSC-Shreveport. References 1. Anderson KC, Pazdur R, Farrell SN-38 in vitro AT: Development of effective new treatments for multiple myeloma. J Clin Oncol 2005, 28:7207–7211.CrossRef 2. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006, 24:431–436.PubMedCrossRef 3. Gay F, Hayman SR, Lacy MQ, Buadi F, Gertz MA, Lazertinib in vitro Kumar S, Dispenzieri A, Mikhael JR, Bergasagel PL, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Witzig TE, Fonseca
R, Kyle RA, Stewart AK, Rajkumar SV: Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood 2010, 115:1343–1350.PubMedCrossRef 4. Rajkumar SV, Jacobs S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp RR, Eastern Cooperative Oncology Group: Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized controlled trial. Lancet Oncol 2010, 11:29–37.PubMedCrossRef
5. Turturro F, Friday E, Welbourne T: Hyperglycemia Rigosertib mw regulates thioredoxin-ROS activity through induction of thioredoxin-interacting protein (TXNIP) in metastatic breast cancer-derived cells MDA-MB-231. BMC Cancer 2007, 7:96–102.PubMedCrossRef 6. Turturro F, Burton G, Friday E: Hyperglycemia-induced thioredoxin-interacting protein expression differs in breast cancer-derived cells and regulates paclitaxel IC50. Clin Cancer Res 2007, 13:3724–3730.PubMedCrossRef however 7. Nishiyama A, Matsui M, Iwata S, Hirota K, Nakamura H, Takagi Y, Sono H, Gon Y, Yodoi J: Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein as a negative regulator of thioredoxin function and expression. J Biol Chem 1999, 274:21645–21650.PubMedCrossRef 8. Junn E, Han SH, Im JY, Yang Y, Cho EW, Um HD, Kim DK, Lee KW, Han PL, Rhee SG, Choi I: Vitamin D3 up-regulated protein 1 mediates oxidative stress via suppressing the thioredoxin function. J Immunol 2000, 164:6287–6295.PubMed 9. Shalev A, Pise-Masison CA, Radonovich M, Hoffman SC, Hirshberg B, Brady JN, Harlan DM: Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway. Endocrinology 2002, 143:3695–3698.PubMedCrossRef 10.